Literature DB >> 24778292

The RESTORE trial: what did we learn about multiple sclerosis?

Steven Karceski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24778292     DOI： 10.1212/WNL.0000000000000423

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  1 in total

1.  New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies.

Authors:  T Sehr; U Proschmann; K Thomas; M Marggraf; E Straube; H Reichmann; A Chan; T Ziemssen
Journal:  J Neuroinflammation       Date:  2016-06-27       Impact factor: 8.322
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.